The regulation of probiotic products and their health claims varies significantly across jurisdictions, creating challenges for manufacturers seeking to market products internationally. Probiotics can be classified as foods, dietary supplements, drugs, or biologics depending on the intended use and the regulatory framework of each country. The scientific substantiation required for health claims is a central issue in probiotic regulation.
Regulatory Classification
In the United States, probiotics are typically marketed as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA) of 1994, or as Generally Recognized as Safe (GRAS) ingredients in conventional foods. If a therapeutic claim is made (e.g., “treats diarrhea”), the product is regulated as a drug requiring FDA approval through a New Drug Application (NDA). The FDA has not yet established a formal regulatory pathway specifically for probiotics, though guidance documents address live biotherapeutic products.
In the European Union, probiotics in foods are regulated under Novel Food Regulation (EU) 2015/2283 and the Nutrition and Health Claims Regulation (EC) 1924/2006. The European Food Safety Authority (EFSA) has rejected the vast majority of submitted probiotic health claims due to insufficient characterization of the strain, inadequate human intervention studies, or lack of a cause-effect relationship. As a result, the term “probiotic” is effectively prohibited on food labels in the EU unless accompanied by an authorized health claim.
Health Claim Substantiation
Scientific substantiation of probiotic health claims requires well-designed human intervention studies demonstrating a statistically significant and clinically meaningful benefit. Key requirements include: strain-level identification using genotypic methods (whole genome sequencing), characterization of the strain’s safety profile (antibiotic resistance screening, absence of virulence factors), dose-response studies establishing the effective dose, and confirmation of viability at the end of shelf-life at the labeled dose.
The International Scientific Association for Probiotics and Prebiotics (ISAPP) has published consensus guidelines on the minimum requirements for probiotic claims, including the need for randomized, placebo-controlled, double-blind trials conducted in the target population. The use of systematic reviews and meta-analyses is increasingly required to support broad health claims.
Labeling Requirements
Probiotic product labels must include the genus, species, and strain designation (e.g., Lactobacillus rhamnosus GG), the minimum viable count at end of shelf-life (typically expressed as colony-forming units or CFU), storage conditions, and serving size. In Canada, Health Canada requires that probiotic products meet specific criteria for each claimed health benefit, with authorized strain-specific health claims listed in the Health Canada monographs.
Japan has the longest history of probiotic regulation through the Foods for Specified Health Uses (FOSHU) system, where products bearing health claims must undergo individual review and approval by the Consumer Affairs Agency, demonstrating both efficacy and safety through human clinical trials.
Quality Control and Stability
Manufacturers must demonstrate probiotic stability throughout the product’s shelf-life, including survival under anticipated storage conditions (temperature, humidity, oxygen exposure). Overages are commonly added to ensure the labeled CFU count is maintained until the expiration date. Accelerated stability studies (e.g., 40°C/75% RH for 6 months) are used to predict shelf-life, though real-time studies are ultimately required for regulatory submissions. Regulatory compliance is essential for marketing probiotic products. Quality control during starter culture production ensures label claims are met. Prebiotics and synbiotics face similar regulatory challenges regarding health claims.
